In August 2023, the Food and Drug Administration issued two draft guidance, both related to the development of biosimilar products, entitled “Formal Meetings between the FDA and Sponsors or Applicants ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback